1 / 17

FLT3 Inhibitors Market Analysis and Forecast, 2022-2032

The global FLT3 inhibitors market is expected to reach $2,061.3 million in 2032 from $400.9 million in 2021 at a CAGR of 14.88% during the forecast period 2022-2032.

bisreports
Download Presentation

FLT3 Inhibitors Market Analysis and Forecast, 2022-2032

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FLT3 Inhibitors Market - A Global and Country Analysis Table of Content Focus on Commercialized Therapy, Potential Pipeline Product, and Region Analysis and Forecast: 2022-2032 FLT3 Inhibitors Market August 2022 All rights reserved at BIS Research Inc. 1

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people FLT3 Inhibitors Market or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. All rights reserved at BIS Research Inc. 2

  3. Table of Content Executive Summary ........................................................................ 16 1.Market ...................................................................................... 21 1.1 Product Definition ............................................................................................ 22 1.1.1Inclusion and Exclusion ............................................................................. 22 1.2 Market Scope ................................................................................................... 22 1.2.1Key Questions Answered in This Report .................................................. 24 1.3 Research Methodology ................................................................................... 25 1.3.1Global FLT3 inhibitors Market: Research Methodology .......................... 25 1.3.2Data Sources ............................................................................................... 26 1.3.2.1 Primary Data Sources ...................................................................................... 26 1.3.2.2 Secondary Data Sources ................................................................................. 26 1.3.3Market Estimation Model ............................................................................ 27 1.3.4Criteria for Company Profiling ................................................................... 29 1.4 Market Overview .............................................................................................. 29 1.4.1Introduction ................................................................................................. 29 1.4.2Current Market Size and Growth Potential, $Million, 2021-2032 ............. 30 1.4.3Types of FLT3 Gene Mutations Involved in AML ...................................... 30 1.4.3.1 FLT3-ITD Mutation ........................................................................................... 31 1.4.3.2 FLT3-TKD Mutation .......................................................................................... 31 1.4.4Mechanism of FLT3 Inhibitors .................................................................... 31 1.4.5Classification of FLT3 Inhibitors ................................................................ 32 1.4.6Resistance to AML Therapy Targeted at FLT3 .......................................... 33 1.4.7Epidemiology of FLT3 Mutated Acute Myeloid Leukemia ........................ 34 FLT3 Inhibitors Market 1.4.7.1 Global Epidemiology of FLT3 Mutated Acute Myeloid Leukemia ...................... 35 1.4.7.2 North America Epidemiology of FLT3 Mutated Acute Myeloid Leukemia .......... 35 1.4.7.3 Europe Epidemiology of FLT3 Mutated Acute Myeloid Leukemia ..................... 36 All rights reserved at BIS Research Inc. 3

  4. 1.4.7.4 China Epidemiology of FLT3 Mutated Acute Myeloid Leukemia ....................... 38 1.4.7.5 Japan Epidemiology of FLT3 Mutated Acute Myeloid Leukemia ....................... 38 1.4.8Role of Companion Diagnostics in FLT3 Inhibitors Market ..................... 39 1.4.8.1 Drug-Diagnostic Co-Development .................................................................... 39 1.4.8.2 Companion Diagnostic Tests for FLT3 Mutated Acute Myeloid Leukemia ........ 40 1.4.8.2.1LeukoStrat CDx FLT3 Mutation Assay..................................................................... 41 1.4.8.2.2Dovitinib DRP Companion Diagnostic ..................................................................... 41 1.4.9Pipeline Analysis ......................................................................................... 41 1.4.9.1 By Clinical Phase ............................................................................................. 41 2. Industry Analysis ..................................................................... 44 2.1 Overview ........................................................................................................... 45 2.2 Legal Requirements and Frameworks in the U.S. ......................................... 45 2.2.1Clinical Trial Authorization ......................................................................... 45 2.2.2Marketing Authorization ............................................................................. 45 2.2.3Post-Authorization Regulations ................................................................. 48 2.3 Legal Requirements and Frameworks in Europe .......................................... 49 2.4 Legal Requirements and Frameworks in Japan ............................................ 51 2.5 Reimbursement and Cost Analysis ................................................................ 52 2.5.1U.S. ............................................................................................................... 52 2.5.2Europe .......................................................................................................... 53 3. Market Dynamics ..................................................................... 55 3.1 Overview ........................................................................................................... 56 3.2 Impact Analysis ............................................................................................... 56 3.3 Market Drivers .................................................................................................. 57 3.3.1Increasing Incidence of Acute Myeloid Leukemia .................................... 57 FLT3 Inhibitors Market 3.3.2Introduction of Novel Products .................................................................. 59 3.3.3Rising Research and Development Investments ...................................... 59 All rights reserved at BIS Research Inc. 4

  5. 3.4 Market Restraints ............................................................................................. 60 3.4.1High Treatment Cost Impacting the Adoption Rate .................................. 60 3.4.2Disease Relapse in FLT3 Mutated AML ..................................................... 61 3.5 Market Opportunities ....................................................................................... 63 3.5.1Massive Scope in Emerging Markets ......................................................... 63 4.Competitive Landscape ............................................................ 64 4.1 Overview ........................................................................................................... 65 4.2 Key Developments and Strategies ................................................................. 65 4.2.1Regulatory and Legal Activities ................................................................. 66 4.2.2Product Approvals and Launches ............................................................. 67 4.2.3Partnerships and Alliances ........................................................................ 68 4.2.4Other Developments ................................................................................... 69 4.3 Market Share Analysis (by Company), 2021 .................................................. 70 4.4 Growth-Share Analysis ................................................................................... 71 5.Global FLT3 inhibitors Market (by Commercialized Therapies), $Million, 2021-2032................................................................... 73 5.1 Overview ........................................................................................................... 74 5.2 Type 1 FLT3 Inhibitors .................................................................................... 75 5.2.1Xospata (Gilteritinib) ................................................................................... 75 5.2.2Rydapt (Midostaurin) ................................................................................... 77 5.3 Type 2 FLT3 Inhibitors .................................................................................... 78 5.3.1Vanflyta (Quizartinib) .................................................................................. 78 6.Global FLT3 inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032................................................................... 81 FLT3 Inhibitors Market 6.1 Overview ........................................................................................................... 82 6.2 Crenolanib ........................................................................................................ 83 6.2.1Crenolanib for Indication 1 (Newly Diagnosed FLT3 Mutated AML) ....... 85 All rights reserved at BIS Research Inc. 5

  6. 6.2.1.1 Safety and Efficacy Results of Crenolanib for Newly Diagnosed FLT3 Mutated AML .................................................................................................... 85 6.2.2Crenolanib for Indication 2 (Relapsed/Refractory FLT3 Mutated AML) ............................................................................................................. 86 6.2.2.1 Safety and Efficacy Results of Crenolanib for Relapsed/Refractory FLT3 Mutated AML .................................................................................................... 87 6.3 Dovitinib ........................................................................................................... 87 6.3.1Safety and Efficacy Results of Dovitinib for Metastatic Renal Cell Carcinoma .................................................................................................... 89 6.4 SKLB1028 ......................................................................................................... 90 7.Global FLT3 inhibitors Market (by Region), $Million, 2021- 2032 ......................................................................................... 92 7.1 Overview ........................................................................................................... 93 7.2 North America .................................................................................................. 94 7.2.1U.S. ............................................................................................................... 96 7.2.1.1 Commercialized Products ................................................................................ 96 7.2.1.2 Market Size and Forecast ................................................................................ 96 7.2.2Canada ......................................................................................................... 97 7.2.2.1 Commercialized Products ................................................................................ 97 7.2.2.2 Market Size and Forecast ................................................................................ 97 7.3 Europe .............................................................................................................. 98 7.3.1Germany ..................................................................................................... 101 7.3.1.1 Market Size and Forecast .............................................................................. 101 7.3.2Italy ............................................................................................................. 102 7.3.2.1 Market Size and Forecast .............................................................................. 102 7.3.3France ......................................................................................................... 103 FLT3 Inhibitors Market 7.3.3.1 Market Size and Forecast .............................................................................. 103 7.3.4U.K. ............................................................................................................. 104 7.3.4.1 Market Size and Forecast .............................................................................. 104 All rights reserved at BIS Research Inc. 6

  7. 7.3.5Spain ........................................................................................................... 105 7.3.5.1 Market Size and Forecast .............................................................................. 105 7.3.6Rest-of-Europe........................................................................................... 106 7.3.6.1 Market Size and Forecast .............................................................................. 106 7.4 Asia-Pacific .................................................................................................... 106 7.4.1Japan .......................................................................................................... 109 7.4.1.1 Commercialized Products .............................................................................. 109 7.4.1.2 Market Size and Forecast .............................................................................. 109 7.4.2China .......................................................................................................... 110 7.4.2.1 Commercialized Products .............................................................................. 110 7.4.2.2 Market Size and Forecast .............................................................................. 110 7.4.3Rest-of-Asia-Pacific ................................................................................... 111 7.4.3.1 Market Size and Forecast .............................................................................. 111 7.5 Rest-of-the-World .......................................................................................... 112 8.Company Profiles ................................................................... 113 8.1 Overview ......................................................................................................... 114 8.2 Cullinan Oncology, LLC ................................................................................ 115 8.2.1Company Overview ................................................................................... 115 8.2.2Role of Cullinan Oncology, LLC in the Global FLT3 inhibitors Market ......................................................................................................... 115 8.2.3Key Competitors of the Company ............................................................ 116 8.2.4Key Insights about Financial Health of the Company ............................ 116 8.2.5Recent Developments ............................................................................... 116 8.2.6Analyst’s Perspective ............................................................................... 117 8.3 Astellas Pharma Inc. ...................................................................................... 118 FLT3 Inhibitors Market 8.3.1Company Overview ................................................................................... 118 8.3.2Role of Astellas Pharma Inc. in the Global FLT3 inhibitors Market ...... 118 8.3.3Key Competitors of the Company ............................................................ 119 All rights reserved at BIS Research Inc. 7

  8. 8.3.4Financials ................................................................................................... 119 8.3.5Key Insights about Financial Health of the Company ............................ 120 8.3.6Recent Developments ............................................................................... 121 8.3.7Analyst’s Perspective ............................................................................... 121 8.4 Allarity Therapeutics, Inc. ............................................................................. 122 8.4.1Company Overview ................................................................................... 122 8.4.2Role of Allarity Therapeutics, Inc. in the Global FLT3 inhibitors Market ......................................................................................................... 122 8.4.3Key Competitors of the Company ............................................................ 123 8.4.4Recent Developments ............................................................................... 123 8.4.5Analyst’s Perspective ............................................................................... 123 8.5 AROG Pharmaceuticals, Inc. ........................................................................ 125 8.5.1Company Overview ................................................................................... 125 8.5.2Role of AROG Pharmaceuticals, Inc. in the Global FLT3 inhibitors Market ......................................................................................................... 125 8.5.3Key Competitors of the Company ............................................................ 126 8.5.4Analyst’s Perspective ............................................................................... 126 8.6 Aptose Biosciences Inc................................................................................. 127 8.6.1Company Overview ................................................................................... 127 8.6.2Role of Aptose Biosciences Inc. in the Global FLT3 inhibitors Market ......................................................................................................... 127 8.6.3Key Competitors of the Company ............................................................ 128 8.6.4Key Insights about Financial Health of the Company ............................ 128 8.6.5Recent Developments ............................................................................... 128 8.6.6 Analyst’s Perspective ............................................................................... 129 FLT3 Inhibitors Market 8.7 Novartis International AG.............................................................................. 130 8.7.1Company Overview ................................................................................... 130 All rights reserved at BIS Research Inc. 8

  9. 8.7.2Role of Novartis International AG in the Global FLT3 inhibitors Market ......................................................................................................... 130 8.7.3Key Competitors of the Company ............................................................ 131 8.7.4Financials ................................................................................................... 131 8.7.5Key Insights about Financial Health of the Company ............................ 133 8.7.6Analyst’s Perspective ............................................................................... 133 8.8 Daiichi Sankyo Company, Limited ............................................................... 134 8.8.1Company Overview ................................................................................... 134 8.8.2Role of Daiichi Sankyo Company, Limited. in Global FLT3 inhibitors Market ......................................................................................................... 134 8.8.3Key Competitors of the Company ............................................................ 135 8.8.4Financials ................................................................................................... 135 8.8.5 Key Insights about Financial Health of the Company ............................ 137 8.8.6Recent Developments ............................................................................... 137 8.8.7Analyst’s Perspective ............................................................................... 137 8.9 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. ............................... 139 8.9.1Company Overview ................................................................................... 139 8.9.2Role of CSPC ZhongQi Pharmaceutical Technology Co., Ltd. in the Global FLT3 Inhibitors Market .................................................................. 139 8.9.3Key Competitors of the Company ............................................................ 140 8.9.4Financials ................................................................................................... 140 8.9.5Key Insights about Financial Health of the Company ............................ 142 8.9.6Analyst’s Perspective ............................................................................... 142 8.10FUJIFILM Pharmaceuticals U.S.A., Inc. ....................................................... 144 8.10.1Company Overview ................................................................................... 144 FLT3 Inhibitors Market 8.10.2Role of FUJIFILM Pharmaceuticals U.S.A., Inc. in the Global FLT3 Inhibitors Market........................................................................................ 144 8.10.3Key Competitors of the Company ............................................................ 145 All rights reserved at BIS Research Inc. 9

  10. 8.10.4Analyst’s Perspective ............................................................................... 145 8.11Jiangsu HengRui Medicine Co., Ltd. ............................................................ 146 8.11.1Company Overview ................................................................................... 146 8.11.2Role of Jiangsu HengRui Medicine Co., Ltd. in the Global FLT3 Inhibitors Market........................................................................................ 146 8.11.3Key Competitors of the Company ............................................................ 147 8.11.4Financials ................................................................................................... 147 8.11.5Key Insights about Financial Health of the Company ............................ 148 8.11.6Analyst’s Perspective ............................................................................... 148 FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 10

  11. List of Figures Figure 1:FLT3 Inhibitors Approved by U.S. Food and Drug Administration (FDA), 2015-2021 Figure 2:FLT3 Inhibitors Global Clinical Trials (by Phase) Figure 3:Global FLT3 Inhibitors Market (by Commercialized Therapies), $Million, 2021-2032 Figure 4:Global FLT3 Inhibitors Market: Impact Analysis of Market Drivers and Restraints Figure 5:Global FLT3 Inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032 Figure 6:Global FLT3 Inhibitors Market (by Region), $Million, 2021-2032 Figure 7:Global FLT3 inhibitors Market Segmentation Figure 8:Global FLT3 inhibitors Market: Research Methodology Figure 9:Primary Research Methodology Figure 10:Bottom-Up Approach (Segment-Wise Analysis) Figure 11:Step by Step Approach Figure 12:Global FLT3 Inhibitors Market, $Million, 2021-2032 Figure 13:FLT3 Gene Mutations in AML Patients Figure 14:Classification of FLT3 Inhibitors Figure 15:Common and Notable Toxicities Associated with FLT3 Inhibitors Figure 16:Estimated Global Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia, 2021-2032 Figure 17:Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in North America, 2021-2032 Figure 18:Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in Europe, 2021-2032 Figure 19:Percentage of FLT3 Mutated Acute Myeloid Leukemia Prevalence (by Country), 2021 Figure 20:Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in China, 2021-2032 Figure 21:Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in Japan, 2021-2032 Figure 22:Drug Diagnostic Co-Development Model Figure 23:FLT3 Inhibitors Emerging Therapies: Developmental Phases Figure 24:Clinical Trial Authorization for FLT3 Inhibitors Figure 25:Process for Obtaining Marketing Authorization Figure 26:Procedures Offered by the Food and Drug Administration (FDA) for Drugs Intended to Treat Serious Health Conditions Figure 27:U.S. Food and Drug Administration Review Timeline Figure 28:EMA Review Timeline Figure 29:Current Reimbursement Scenario in Europe Figure 30:Global Incidence of Acute Myeloid Leukemia, 2015-2019 Figure 31:Global Incidence of FLT3 Mutated Acute Myeloid Leukemia, 2016-2020 Figure 32:Number of Clinical Trials for FLT3 Inhibitors (by Major Player) Figure 33:Mechanisms Responsible for Resistance to FLT3 Inhibitors FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 11

  12. Figure 34:Clinical Strategies to Overcome Drug Resistance in FLT3-ITD AML Figure 35:Share of Key Developments and Strategies, January 2019-June 2022 Figure 36:Regulatory and Legal Activities (by Company), January 2019-June 2022 Figure 37:Product Approvals and Launches (by Company), January 2019-June 2022 Figure 38:Partnerships and Alliances (by Company), January 2019-June 2022 Figure 39:Market Share Analysis of the Global FLT3 Inhibitors market (by Company), 2021 Figure 40:Growth-Share Matrix for the Global FLT3 inhibitors Market (by Company), 2021 Figure 41:Global FLT3 Inhibitors Market (by Commercialized Therapies), $Million, 2021-2032 Figure 42:Global FLT3 Inhibitors Market (by Type 1 FLT3 Inhibitors), $Million, 2021-2032 Figure 43:Global FLT3 Inhibitors Market (Xospata, by Type 1 FLT3 Inhibitors), $Million, 2021-2032 Figure 44:Global FLT3 Inhibitors Market (Rydapt, by Type 1 FLT3 Inhibitors), $Million, 2021-2032 Figure 45:Global FLT3 Inhibitors Market (Vanflyta, by Type 2 FLT3 Inhibitors), $Million, 2021-2032 Figure 46:Global FLT3 Inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032 Figure 47:Global FLT3 Inhibitors Market (Crenolanib), $Million, 2021-2032 Figure 48:Crenolanib Phase III Clinical Trial Design for Newly Diagnosed FLT3 Mutated AML Figure 49:Crenolanib Phase III Clinical Trial Design for Relapsed/Refractory FLT3 Mutated AML Figure 50:Global FLT3 Inhibitors Market (Dovitinib), $Million, 2021-2032 Figure 51:Dovitinib Phase III Clinical Trial Design for Metastatic Renal Cell Carcinoma Figure 52:Global FLT3 Inhibitors Market (SKLB1028), $Million, 2021-2032 Figure 53:SKLB1028 Phase III Clinical Trial Design for Relapsed/Refractory FLT3 Mutated AML Figure 54:Global FLT3 Inhibitors Market (by Region), $Million, 2021-2032 Figure 55:North America FLT3 Inhibitors Market, $Million, 2021-2032 Figure 56:North America: Market Dynamics Figure 57:North America FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032 Figure 58:U.S. FLT3 Inhibitors Market, $Million, 2021-2032 Figure 59:Canada FLT3 Inhibitors Market, $Million, 2021-2032 Figure 60:Europe FLT3 Inhibitors Market, $Million, 2021-2032 Figure 61:Europe: Market Dynamics Figure 62:Europe FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032 Figure 63:Germany FLT3 Inhibitors Market, $Million, 2021-2032 Figure 64:Italy FLT3 Inhibitors Market, $Million, 2021-2032 Figure 65:France FLT3 Inhibitors Market, $Million, 2021-2032 Figure 66:U.K. FLT3 Inhibitors Market, $Million, 2021-2032 Figure 67:Spain FLT3 Inhibitors Market, $Million, 2021-2032 Figure 68:Rest-of-Europe FLT3 Inhibitors Market, $Million, 2021-2032 Figure 69:Asia-Pacific FLT3 Inhibitors Market, $Million, 2021-2032 Figure 70:Asia-Pacific: Market Dynamics Figure 71:Asia-Pacific FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032 Figure 72:Japan FLT3 Inhibitors Market, $Million, 2021-2032 Figure 73:China FLT3 Inhibitors Market, $Million, 2021-2032 FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 12

  13. Figure 74:Rest-of-Asia-Pacific FLT3 Inhibitors Market, $Million, 2021-2032 Figure 75:Rest-of-the-World FLT3 Inhibitors Market, $Million, 2021-2032 Figure 76:Total Number of Companies Profiled Figure 77:Cullinan Oncology, LLC: Pre-Clinical and Clinical Assets Figure 78:Cullinan Oncology, LLC: R&D Expenditure, $Million, 2019-2021 Figure 79:Astellas Pharma Inc.: Commercialized Product Figure 80:Astellas Pharma Inc.: Overall Financials, $Million, 2019-2021 Figure 81:Astellas Pharma Inc.: Revenue (by Region), $Million, 2019-2021 Figure 82:Astellas Pharma Inc.: R&D Expenditure, $Million, 2019-2021 Figure 83:Allarity Therapeutics, Inc.: Pre-Clinical and Clinical Assets Figure 84:AROG Pharmaceuticals, Inc.: Pre-Clinical and Clinical Assets Figure 85:Aptose Biosciences Inc.: Pre-Clinical and Clinical Assets Figure 86:Aptose Biosciences Inc.: R&D Expenditure, $Million, 2019-2021 Figure 87:Novartis International AG: Commercialized Product Figure 88:Novartis International AG: Overall Financials, $Million, 2019-2021 Figure 89:Novartis International AG: Revenue (by Segment), $Million, 2019-2021 Figure 90:Novartis International AG: Revenue (by Region), $Million, 2019-2021 Figure 91:Novartis International AG: R&D Expenditure, $Million, 2019-2021 Figure 92:Daiichi Sankyo Company, Limited: Commercialized Product Figure 93:Daiichi Sankyo Company, Limited.: Overall Financials, $Million, 2019-2021 Figure 94:Daiichi Sankyo Company, Limited.: Revenue (by Segment), $Million, 2019-2021 Figure 95:Daiichi Sankyo Company, Limited.: Revenue (by Region), $Million, 2019-2021 Figure 96:Daiichi Sankyo Company, Limited.: R&D Expenditure, $Million, 2019-2021 Figure 97:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Pre-Clinical and Clinical Assets Figure 98:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Overall Financials, $Million, 2019- 2021 Figure 99:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Revenue (by Segment), $Million, 2019-2021 Figure 100:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Revenue (by Region), $Million, 2019-2021 Figure 101:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: R&D Expenditure, $Million, 2019- 2021 Figure 102:FUJIFILM Pharmaceuticals U.S.A., Inc.: Pre-Clinical and Clinical Assets Figure 103:Jiangsu HengRui Medicine Co., Ltd.: Pre-Clinical and Clinical Assets Figure 104:Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021 Figure 105:Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021 FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 13

  14. List of Tables Table 1: Table 2: Table 3: Table 4: Table 5: Table 6: Table 7: Table 8: Table 9: Table 10:Approved FLT3 Inhibitors Products in Developed Nations Table 11:Commercialized Products in the Global FLT3 Inhibitors Market Table 12:Potential Pipeline Products to Global FLT3 Inhibitors Market Table 13:List of Selective Commercialized FLT3 Inhibitors in the U.S. Table 14:List of Selective Commercialized FLT3 Inhibitors in Canada Table 15:List of Selective Commercialized FLT3 Inhibitors in Europe Table 16:List of Selective Commercialized FLT3 Inhibitors in Japan Table 17:List of Selective Commercialized FLT3 Inhibitors in China Mechanisms of Resistance of FLT3-Mutated AML Cells to FLT3 Inhibitors Prominent CDx Tests for FLT3 Mutated AML Emerging Phase III FLT3 Therapeutics Pipeline Annual Cost of Approved FLT3 Inhibitors in the U.S. Reimbursement Scenario of Approved FLT3 Inhibitors in the U.S. Likert Scale Impact Analysis of Market Drivers Impact Analysis of Market Restraints Approved FLT3 Inhibitors for FLT3 Mutated AML FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 14

  15. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Know More FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 15

  16. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 FLT3 Inhibitors Market All rights reserved at BIS Research Inc. 16

  17. BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, FLT3 Inhibitors Market Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com All rights reserved at BIS Research Inc. 17

More Related